CAR T-Cell Therapy for Multiple Myeloma Market Expected to Grow at a 27.56% CAGR by 2030

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CAR T-Cell Therapy For Multiple Myeloma Market- by Therapy Type (Bb2121, JNJ-68284528 (LCAR-B38M), P-BCMA-101, CAR-CD44V6 and Others), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the latest research by InsightAce Analytic, the global CAR T-Cell Therapy For Multiple Myeloma market is expected to show a CAGR of 27.56% during a forecast period of 2022-2030.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1088

Chimeric Antigen Receptor (CAR) T-cell therapy is an innovative treatment that involves the genetic modification of a patient's T cells to express chimeric antigen receptors (CARs) that target specific tumor antigens. This process includes the extraction of the patient's T cells, their ex vivo genetic modification and multiplication, and subsequent reinfusion into the patient. CAR-T cell therapy has been approved for the treatment of certain types of blood cancer. Multiple myeloma, a form of blood cancer, affects plasma cells - which are essential for fighting infections. In multiple myeloma, malignant cells accumulate in the bone marrow (the soft, spongy tissue at the core of bones), disrupting the normal function of plasma cells.

The global market for CAR T-cell therapy in multiple myeloma is projected to expand due to the increasing prevalence of the disease. Market growth is expected to be supported by the development of promising multiple myeloma treatment candidates currently in the pipeline. Additionally, rising financial support from both governmental and non-governmental organizations for CAR-T therapy development is expected to drive market expansion. These entities are providing funding for research and development (R&D) of CAR-T therapies and supporting patient access to treatment for acute lymphoblastic leukemia (ALL). However, the substantial costs associated with research and development in CAR T-cell therapy may pose a significant challenge to market growth over the forecast period.

North America is anticipated to lead the CAR T-cell therapy market for multiple myeloma, driven by increasing R&D activities and the heightened focus of biopharmaceutical companies on developing advanced treatments such as CAR-T cell therapy. Moreover, the Asia-Pacific CAR T-cell therapy market for multiple myeloma is expected to experience significant growth due to the rising incidence of cancer and increasing research and development efforts. The expanding focus of biopharmaceutical companies on innovative therapies, including CAR-T cell treatments, is further expected to accelerate market growth in the region.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Major market players operating in the CAR T-Cell Therapy For Multiple Myeloma market include
Bluebird bio/Celgene, Janssen Research & Development, Poseida Therapeutics, MolMed S.p.A., Celgene Corporation, Cartesian Therapeutics, CARsgen Therapeutics and Precision BioSciences.

Recent collaborations and agreements in the market:
• In 2019, CellforCure was purchased by Novartis, a major pharmaceutical firm with headquarters in Switzerland, for an unknown sum. The acquisition aims to improve Novartis' internal capability for producing cell and gene treatments. A manufacturing facility for cell and gene therapy is offered by CellforCure, a contract development and manufacturing organization (CDMO) with headquarters in France.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1088

Market Segments
Global CAR T-Cell Therapy For Multiple Myeloma Market, by Therapy Type, 2022-2030 (Value US$ Mn)
• Bb2121
• JNJ-68284528 (LCAR-B38M)
• P-BCMA-101
• CAR-CD44V6
• Others
Global CAR T-Cell Therapy For Multiple Myeloma Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America CAR T-Cell Therapy For Multiple Myeloma Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe CAR T-Cell Therapy For Multiple Myeloma Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific CAR T-Cell Therapy For Multiple Myeloma Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America CAR T-Cell Therapy For Multiple Myeloma Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa CAR T-Cell Therapy For Multiple Myeloma Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global CAR T-Cell Therapy For Multiple Myeloma market
 To receive an industry overview and future trends of the CAR T-Cell Therapy For Multiple Myeloma market
 To analyze the CAR T-Cell Therapy For Multiple Myeloma market drivers and challenges
 To get information on the CAR T-Cell Therapy For Multiple Myeloma market value (US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the CAR T-Cell Therapy For Multiple Myeloma market industry

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.